oral in Biological Technology

InterMune Reports Second Quarter 2009 Financial Results and Business Highlights

... profile of pirfenidone, has been accepted for an oral presentation at the 2009 European Respiratory ... for pirfenidone in IPF were presented in an oral late-breaker session on May 19 at the ... ------------- Pirfenidone ----------- oral presentation on pirfenidone at ERS ...

Shire plc: Core Portfolio of Products Delivers 20% Sales Growth

... post-dose. VYVANSE is now the first and only oral ADHD stimulant treatment to have 13 hour ... 2009 of $4.9 million (2008: $nil). US oral mesalamine market share Shire's average market share of the US oral mesalamine market rose to 31.8% for the three ...

Oramed Pharmaceuticals was Awarded a NIS 3.1 Million Grant From the Israeli Office of the Chief Scientist

... ( http://www.oramed.com ), a developer of oral delivery systems, today reported that its wholly ... support further R&D and clinical study of its oral Insulin capsule and oral GLP1-Analog. Nadav Kidron Esq., CEO of ...

DOR BioPharma Receives FDA Orphan Drug Designation for orBec(R) for the Treatment of Chronic Gastrointestinal GVHD

... (FDA) has granted Orphan Drug Designation to oral BDP (beclomethasone 17,21-dipropionate, or ... allergic rhinitis and asthma. orBec((R)) and oral BDP are currently in development by DOR for the ... trial in the prevention of acute GVHD. oral BDP may also have application in treating other ...

ImmuneRegen BioSciences Confirms Homspera's Therapeutic Anti-Influenza Effect on Pandemic H1N1 Influenza Virus After Oral Administration

... 1-receptor agonist Homspera(R) is both active on oral administration and provides therapeutic effects ... bioavailability studies in rats had revealed the oral administration of Homspera resulted in measurable ... and accumulation in lungs was found after both oral and intra-duodenal administration in studies ...

MuGard Data From UK Study Shows Prevention of Oral Mucositis in Head and Neck Cancer Patients

... treatment in the UK showing prevention of oral mucositis. In a multi-center study expected to ... none of these patients have experienced any oral mucositis. "The initial feedback from ... for head and neck cancer experience some level of oral mucositis. This condition varies from a low ...

Study Published in Child and Adolescent Psychiatry and Mental Health Demonstrated Once-Daily Vyvanse(R) (lisdexamfetamine dimesylate) CII Provided Significant Improvement of ADHD Symptoms for Children at 13 Hours After Administration

... the first to have shown duration of effect of an oral ADHD stimulant in children aged 6 to 12 at 13 ... postdose. Vyvanse is now the first and only oral ADHD stimulant treatment to have efficacy at 13 ... is covalently bonded to l-lysine, and after oral ingestion it is converted to pharmacologically ...

Oramed Pharmaceuticals Reports Positive Results From a Study of Oral Insulin Capsule on Type 1 Diabetic Patients

... positive results from a Phase 2A study of its oral insulin capsule, ORMD-0801, on type 1 ... in type 1 diabetic patients. Oramed's oral insulin capsule, (ORMD-0801), was well tolerated ... "These results demonstrate that Oramed's oral insulin capsule had a good safety profile and was ...

OncologyRx Care Advantage(TM) Specialty Pharmacy Passes $15 Million Milestone in Patient Financial Assistance

... OncologyRx Care Advantage(TM) , its national oral oncology specialty pharmacy service, has exceeded ... medical expenses, "but with the high cost of oral therapies, co-pays can still remain high. Even ... began treating him with Nexavar , an oral multiple kinase inhibitor that has been shown to ...

DOR BioPharma Announces Issuance of European Patent for its LPM(TM) Oral Drug Delivery Technology

... Micelle (LPM(TM)) technology for the improved oral delivery of drugs. The issued European patent, EP ... clearly show that it is a competitive system for oral delivery of drugs, especially those biotechnology ... proceeding towards clinical development of an oral form of the peptide hormone drug leuprolide using ...

Schering-Plough Announces Phase II and III Data for Corifollitropin Alfa

... FSH irrespective of variations in ART procedures. oral presentation at 25th European Society of Human ... efficacy in terms of oocyte and embryo quality. oral presentation at 25th European Society of Human ... are not affected by enodgenous LH levels. oral presentation at 25th European Society of Human ...

DOR BioPharma Announces Publication of orBec(R) Clinical Pulmonary Data in Bone Marrow Transplantation

... The full article, entitled "Influence of oral Beclomethasone Dipropionate on Early ... et al. (A randomized, placebo-controlled trial of oral beclomethasone dipropionate as a ... these observations suggest that a metabolite of oral BDP may be having a beneficial anti-inflammatory ...

Palkion Selects Novel Oral Development Candidate for the Treatment of Anemia

... available Erythropoietins are injectables, an oral agent, as being developed by Palkion, could be ... Inc. is a private early stage company developing oral drugs to treat anemia based on discovery and development of oral agents that inhibit prolyl hydroxylase enzymes. ...

Access Pharmaceuticals Announces Granting of Two US Patents for MuGard(TM)

... to MuGard(TM ), the Company's approved oral rinse product for the management of mucositis ... MuGard is a novel, ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis , a debilitating side effect of many ...

Proteolix Presents Clinical Data from Two Clinical Studies of Carfilzomib in Multiple Myeloma at the 14th Congress of the European Hematology Association

... These data were reported by Dr. Stewart in an oral presentation, titled "# 0474: Safety and Efficacy ... Therapeutics and Drug Resistance session in an oral talk, titled "#1070: PX-171-006: Phase IB ... proteasome inhibitors, including a selective, oral proteasome inhibitor and a selective ...

Orexigen(R) Therapeutics Presents Additional NB-302 Contrave(R) Data at American Diabetes Association (ADA) 69th Scientific Sessions

... SR). These data were presented in one oral and two poster presentations at the American ... Sessions in New Orleans, Louisiana. The oral presentation highlighted the significant ... in the Contrave group were discussed in the oral presentation and reviewed in greater detail in ...

Optimer Pharmaceuticals Announces Lower Recurrence Rates for Fidaxomicin Versus Vancocin(R) in Subgroup Analyses from Its Phase 3 Study for the Treatment of CDI

... demonstrated a lower recurrence rate compared to oral vancomycin (Vancocin(R)) regardless of albumin ... shows that fidaxomicin is more effective than oral vancomycin when it comes to reducing recurrence, ... options for CDI include metronidazole and oral vancomycin. However, approximately 20% to 30% of ...

Peregrine Pharmaceuticals Presents Promising Data From Its Phase II Bavituximab Breast Cancer Trial at 2009 ASCO Annual Meeting

... cancer will be discussed this morning in an oral presentation at the 45th Annual Meeting of the ... W. King, president and CEO of Peregrine. "Our oral presentation today at ASCO exemplifies the ... breast cancer patients will be the subject of an oral presentation at 10:30 AM EDT on June 1, 2009. A ...

Raptiva Withdrawal Offers Upside for Enbrel and Humira According to Latest BioTrends Survey of U.S. Dermatologists

... share leaders for topical agents. Use of oral agents to treat moderate and severe psoriasis declined for the second year in a row. Use of oral agents is divided primarily between methotrexate ... identify methotrexate as the first line oral choice whereas 43% choose Soriatane. On ...

Lexicon to Present Clinical Data for LX1031 and LX1032 at Digestive Disease Week

... announced today that the company will be giving oral presentations on two of its clinical-stage drug development programs: LX1031 , an oral drug candidate for the treatment of irritable bowel syndrome (IBS), and LX1032 , an oral drug candidate for managing gastrointestinal ...

Vaxart Begins Animal Testing of H1N1 Flu Vaccine Candidate

... company focused on the development of oral vaccines, announced today that the company has ... the need for safety testing in animals. "Our oral vaccine could provide an important tool for swine ... company focused on the development of oral vaccines. Vaxart's proprietary approach is ...

Amgen Exercises Option for Exclusive License to Cytokinetics' Cardiac Contractility Program That Includes CK-1827452

... pharmacokinetic profile of both intravenous and oral formulations of CK-1827452 for the potential ... an intravenous formulation together with an oral formulation of CK-1827452 in patients with ... trial designed to evaluate and compare the oral pharmacokinetics of both a modified release and ...

ChemoCentryx's Traficet-EN(TM) Phase II/III Induction Phase Data in Crohn's Disease to be Featured in Oral Presentation at 2009 Digestive Disease Week

... First-in-class oral Therapeutic for IBD with Novel Mode of Action ... company's PROTECT-1 (the Prospective Randomized oral Therapy Evaluation in Crohn's disease Trial) ... Crohn's disease will be presented in an oral session at the upcoming 2009 Digestive Disease ...

Schering-Plough Announces Changes to its Global Collaboration with Novartis to Develop Combination Therapies for Asthma and COPD

... closely by your health care provider and the oral steroids should be reduced slowly. Deaths due to ... have occurred during and after switching from oral steroids to inhaled steroids. Tell your health ... AEROLIZER is not a substitute for inhaled or oral corticosteroids and, in the treatment of asthma, ...

Proteolix to Present Carfilzomib Clinical Data During the 2009 ASCO Annual Meeting

... Myeloma and Advanced Solid Tumors Featured in oral Presentations SOUTH SAN FRANCISCO, May 15 ... will be presented on Monday, June 1 during an oral session by Sundar Jagannath, M.D., Chief of the ... will be presented on Saturday, May 30 during an oral session by Peter Rosen, M.D., Medical Director, ...

DOR BioPharma Reports 1st Quarter 2009 Financial Results and Reviews Recent Accomplishments

... of orBec(R) (oral beclomethasone dipropionate or oral BDP). On January 27, 2009, DOR announced ... of DOR201, a time-release formulation of oral beclomethasone dipropionate (oral BDP) for the ... trial in the prevention of acute GVHD. oral BDP may also have application in treating other ...

OncoGenex Pharmaceuticals Announces Release of Two ASCO Abstracts: Impact of OGX-011 on Survival in Randomized Phase 2 Trial and Phase 1 Safety Data for OGX-427

... release of two abstracts to be presented during oral presentations at the upcoming American Society of ... 2009 for this trial will be presented during an oral presentation at ASCO. Highlights from the ... agent. Updated data will be presented during an oral presentation at ASCO. ...

Results From Phase 3 CAPACITY Program of Pirfenidone in IPF and Study of Predictors of Mortality in IPF to be Presented at ATS

... 8:15 a.m. PDT - - Phase 3 CAPACITY results oral presentation, Tuesday, May 19, 3:35 p.m. PDT - ... Inc. (Nasdaq: ITMN ) today announced that an oral late-breaker presentation and two poster ... two CAPACITY studies will be the subject of an oral late-breaker presentation on Tuesday, May 19. In ...

Lilly Set to Unveil More Than 50 Studies at ASCO 2009

... include: Abstract #CRA8000: oral Presentation: May 31, 2009, 9:00 a.m. ... include: Abstract #CRA5507: oral Presentation: May 31, 2009, 10:30 a.m. ... a.m. Abstract #4503: oral Presentation: June 1, 2009, 4:30 p.m. ...

Pharmasset Reports Fiscal Second Quarter 2009 Financial Results

... reported results from the INFORM-1 trial as an oral late breaker at the European Association for the ... investigate the activity of a combination of two oral antiviral molecules to treat HCV in the absence ... primary focus is on the development of oral therapeutics for the treatment of hepatitis C ...

OncoGenex Pharmaceuticals' Clinical Programs to be Featured in Oral Presentations at the American Society of Clinical Oncology Annual Meeting

... prostate cancer will be featured in an oral presentation at the American Society of Clinical ... candidate, OGX-427, will also be featured in an oral presentation at ASCO. Abstracts will be made ... , on Thursday, May 14 at 6:00 p.m. (EDT). The oral presentations are scheduled for Saturday, May 30 ...

OncoGenex Reports First Quarter Financial Results

... prostate cancer will be featured during an oral presentation at the American Society of Oncology 2009 Annual Meeting. The oral presentation will update the preliminary survival ... receiving chemotherapy without OGX-011. A second oral presentation at the ASCO 2009 Annual Meeting will ...

First oral uveitis drug reduces both inflammation and recurrence in potentially blinding eye disease

... the ability of LX211 (LUVENIQ, voclosporin oral capsule) to significantly improve this chronic ... would be suitable for chronic use as the first oral treatment for this sight-threatening inflammatory ... previously has attempted to demonstrate that an oral medication can successfully treat uveitis, and ...

Anadys Pharmaceuticals Reports First Quarter 2009 Financial Results and Highlights

... ANA598 ANA598 is an investigational oral non-nucleoside polymerase inhibitor that Anadys ... profile of ANA598 at the EASL meeting in an oral presentation titled, "Preclinical Studies of ... ANA773 ANA773 is an oral prodrug of a small molecule inducer of endogenous ...

Idenix Pharmaceuticals Reports Data From Three Hepatitis C Development Programs at the 44th Annual Meeting of the European Association for the Study of the Liver

... include data on IDX184, a once-daily, oral nucleotide polymerase inhibitor prodrug currently ... Inhibitor IDX184 is a liver-targeted, oral nucleotide prodrug designed to enhance the ... no adverse effects in monkeys given daily oral doses of 10 or 100 mg/kg for 7 days. ...

Access Pharmaceuticals Announces the European Launch of MuGard(TM) by its European Partner, SpePharm

... that MuGard(TM), its proprietary polymer-based oral mucositis product has been launched in Germany, ... MuGard is a ready-to-use mucoadhesive oral wound rinse for the management of oral mucositis, a debilitating side effect of many ...

AEterna Zentaris Presents Two Posters on its PI3K Inhibitor Compound, AEZS-126, at AACR Annual Meeting

... Vitro and In Vivo Data Show AEZS-126 as Promising oral Compound for Future Clinical Development in ... and mouse xenograft antitumor studies, the oral bioavailability in mice was determined to be ... antitumor activity was observed at 30mg/kg daily oral administration in Hct116 and A549 models. ...

Poniard Pharmaceuticals to Present Final Data from Picoplatin Phase 1 Clinical Trials at American Association for Cancer Research's 100th Annual Meeting

... -- Phase 1 Data from Colorectal Cancer and oral Picoplatin Trials To Be Presented -- SOUTH ... bioavailability data from its Phase 1 trial of an oral formulation of picoplatin. Details are ... Section 30 A Phase 1 randomized crossover oral picoplatin bioavailability pharmacokinetics ...

BASF Set To Commercialize pro-t-action(TM) Eliminating Caries Causing Bacteria From the Mouth

... integrated into consumer products for daily oral care Full research studies introduced at ... candies, lozenges and chewing gums used for daily oral care. Caries causing bacteria in the oral cavity, like Streptococcus mutans, initiate the ...

DOR BioPharma Reports Year-End 2008 Financial Results and Reviews Recent Accomplishments

... of orBec(R) (oral beclomethasone dipropionate or oral BDP). On January 27, 2009, DOR announced ... of DOR201, a time-release formulation of oral beclomethasone dipropionate (oral BDP) for the ... trial in the prevention of acute GVHD. oral BDP may also have application in treating other ...